Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

In recent years, light-based wellness solutions have gained remarkable popularity in both consumer and healthcare markets. From skincare regimens to comprehensive health treatments, these technologies ...

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...

Award Winner and Clear Choice for RED Light Therapy Award-winning confidence with red light therapy With Clearlight's Red ...

As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

Researchers have found that pharmacy benefit managers (PBMs) -- organizations that negotiate access to medicines for most patients in the United States -- steer patients to use their own pharmacies.

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

The price at which the PBM obtains the drug for its clients is the net price – the list price minus the drugmaker’s discount. If a drugmaker increases its rebate, the net price falls, even if the ...